Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492531 · ClinicalTrials.gov registry record · Phase 2
Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease
A Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00492531 is a Phase 2 study that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 74 participants.
The verdict
NCT00492531, a Phase 2 study, was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study will examine whether the drug sildenafil can lower blood pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) in patients with sickle cell disease and pulmonary hypertension (high blood pressure in the lungs). It will see if this treatment can reduce disease complications, such as shortness of breath, pain crisis, pneumonia, and increase survival. Patients 12 years of age and older with sickle cell disease and pulmonary hypertension may be eligible for this study. Participants are randomly assigned to receive sildenafil or placebo (sugar pill) for 16 weeks. Before starting treatment, patients have baseline studies, including a pregnancy test for females of childbearing age; a chest x-ray; pulmonary function tests to measure how much air the patient can breathe in and out; an echocardiogram (heart ultrasound); a 6-minute walk test to measure exercise capacity; a quality-of-life assessment and a pain inventory. Patients with moderate to severe pulmonary hypertension undergo heart catheterization to evaluate the severity of hypertension before beginning sildenafil therapy. During treatment, patients are monitored with the following: * Blood tests: weeks 6, 10 and 16. * Echocardiogram: weeks 6 and 16. * 6-minute walk test: weeks 6, 10 and 16. * Measurements of weight, blood pressure and heart rate: weeks 6, 10 and 16. * Pregnancy test for women of childbearing age: weeks 6, 10 and 16. * Pain questionnaire once a day for a week: weeks 6 and 1.0 * Quality-of-life questionnaire: week 16. * Heart catheterization: week 16 for patients with moderate to severe hypertension. At the end of the 16-week period, patients may opt to continue to receive sildenafil and monitoring in an open-label phase of the study for up to 1 year.
Interventions
- DRUG Placebo
- DRUG Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492531
The ClinicalTrials.gov registry entry for NCT00492531 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00492531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492531 about?
NCT00492531 is a clinical study titled "Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease". This study will examine whether the drug sildenafil can lower blood pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) in patients with sickle cell disease and pulmonary hypertension (high blood pressure in the lungs). It will see if this treatment can reduce ...
What is the current status of trial NCT00492531?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2007-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00492531?
The interventions under investigation include: Placebo (DRUG), Sildenafil (DRUG).
Who is sponsoring clinical trial NCT00492531?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.